5-Aminolevulinic Acid Protects against Cisplatin-Induced Nephrotoxicity without Compromising the Anticancer Efficiency of Cisplatin in Rats In Vitro and In Vivo
Figure 10
Measurement of heme in the ALA-treated cisplatin-induced AKI rats and NRK-52E cells exposed to cisplatin and ALA + Fe.
(A) Aliquots (100 μg) of protein from renal tissue extracts were used for the heme assay in cisplatin-treated, control, and cisplatin + ALA (both post and pre + post)- treated rats. (B) Aliquots (10 μg) of protein extracts from NRK-52E cells were used for the heme assay in the control as well as the cisplatin-, cisplatin + ALA-, and cisplatin + ALA + Fe-treated NRK-52E cells. Data are the mean ± SEM of six experiments per group. *P<0.05 v.s. control or CDDP, n.s. is not significant by ANOVA.